XGN Stock Forecast 2025-2026
Distance to XGN Price Targets
XGN Price Momentum
10 Quality Stocks Worth Considering Now
Researching Exagen (XGN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on XGN and similar high-potential opportunities.
Latest XGN Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, XGN has a bullish consensus with a median price target of $7.00 (ranging from $5.00 to $8.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $3.56, the median forecast implies a 96.6% upside. This outlook is supported by 5 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ross Osborn at Cantor Fitzgerald, projecting a 124.7% upside. Conversely, the most conservative target is provided by Mark Massaro at BTIG, suggesting a 40.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
XGN Analyst Ratings
XGN Price Target Range
Latest XGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for XGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 13, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $8.00 |
| Jan 3, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $7.00 |
| May 14, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $7.00 |
| Sep 26, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $6.00 |
| Aug 22, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $6.00 |
| May 16, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $6.00 |
| Mar 22, 2023 | BTIG | Mark Massaro | Buy | Maintains | $5.00 |
| Nov 17, 2022 | BTIG | Mark Massaro | Buy | Maintains | $7.00 |
| Nov 15, 2022 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $7.00 |
| May 13, 2022 | Keybanc | Paul Knight | Overweight | Maintains | $17.00 |
| Mar 25, 2022 | Keybanc | Paul Knight | Overweight | Maintains | $20.00 |
| Nov 11, 2021 | Keybanc | Paul Knight | Overweight | Maintains | $30.00 |
| Apr 15, 2021 | Canaccord Genuity | Buy | Initiates | $0.00 | |
| Mar 2, 2021 | Keybanc | Paul Knight | Overweight | Maintains | $33.00 |
| Mar 2, 2021 | KeyBanc | Overweight | Maintains | $0.00 | |
| Nov 10, 2020 | KeyBanc | Overweight | Initiates | $0.00 | |
| Nov 10, 2020 | Keybanc | Overweight | Initiates | $0.00 | |
| Oct 8, 2020 | BTIG | Buy | Initiates | $0.00 | |
| Jun 2, 2020 | Cantor Fitzgerald | Overweight | Assumes | $20.00 | |
| Nov 13, 2019 | Cantor Fitzgerald | Overweight | Maintains | $25.00 |
Exagen Inc. (XGN) Competitors
The following stocks are similar to Exagen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Exagen Inc. (XGN) Financial Data
Exagen Inc. has a market capitalization of $63.72M with a P/E ratio of -4.3x. The company generates $55.64M in trailing twelve-month revenue with a -27.2% profit margin.
Revenue growth is -0.8% quarter-over-quarter, while maintaining an operating margin of -24.8% and return on equity of -93.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Exagen Inc. (XGN) Business Model
About Exagen Inc.
Develops innovative testing solutions for autoimmune diseases.
Exagen Inc. generates revenue by providing advanced diagnostic tests, primarily the AVISE® product, which offers healthcare providers and patients critical insights into autoimmune disorders. The company focuses on enhancing its testing platforms through ongoing research and development, ensuring that it remains at the forefront of autoimmune diagnostics.
By targeting healthcare professionals and patients, Exagen aims to improve patient management and clinical outcomes for chronic autoimmune conditions. The company's commitment to innovation in this specialized field positions it as a significant player in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
174
CEO
Mr. John Aballi
Country
United States
IPO Year
N/A
Website
www.exagen.comExagen Inc. (XGN) Latest News & Analysis
Exagen Inc. will host its Q4 2024 earnings conference call on March 11, 2025, at 8:30 AM ET, featuring executives and analysts from various firms.
Exagen's Q4 earnings call will provide insights into financial performance, strategic direction, and market outlook, influencing investor sentiment and stock valuation.
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
5 days agoExagen Inc. reported record full-year revenue and improved adjusted EBITDA loss and cash use by over 40%. New biomarkers for AVISE CTD were also commercialized.
Exagen Inc.'s record revenue and improved EBITDA loss indicate strong financial health, while new biomarkers enhance product value, potentially boosting investor confidence and stock performance.
Exagen Inc. reported a quarterly loss of $0.20 per share, better than the Zacks estimate of $0.27, and improved from a loss of $0.31 per share a year prior.
Exagen's smaller-than-expected loss signals improving performance, potentially boosting investor confidence and positively impacting stock valuation.
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
19 days agoExagen Inc. (Nasdaq: XGN) will report Q4 and full-year 2024 financial results on March 11, 2025, before market open, followed by a conference call at 8:30 AM ET.
Exagen's upcoming financial results announcement could impact stock performance, offering insights into its growth and market position in the autoimmune testing sector.
Exagen Inc. (Nasdaq: XGN) will participate in upcoming investor conferences, as announced on February 4, 2025.
Exagen's participation in investor conferences signals potential strategic developments and investor engagement, which may influence stock performance and market perception.
Exagen (XGN) shares increased recently with above-average trading volume, but recent earnings estimate revisions may not lead to further price gains soon.
Exagen's share surge and higher trading volume indicate increased investor interest, but potential stagnation in earnings estimates suggests caution for future price movements.
Frequently Asked Questions About XGN Stock
What is Exagen Inc.'s (XGN) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Exagen Inc. (XGN) has a median price target of $7.00. The highest price target is $8.00 and the lowest is $5.00.
Is XGN stock a good investment in 2025?
According to current analyst ratings, XGN has 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.56. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for XGN stock?
Wall Street analysts predict XGN stock could reach $7.00 in the next 12 months. This represents a 96.6% increase from the current price of $3.56. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Exagen Inc.'s business model?
Exagen Inc. generates revenue by providing advanced diagnostic tests, primarily the AVISE® product, which offers healthcare providers and patients critical insights into autoimmune disorders. The company focuses on enhancing its testing platforms through ongoing research and development, ensuring that it remains at the forefront of autoimmune diagnostics.
What is the highest forecasted price for XGN Exagen Inc.?
The highest price target for XGN is $8.00 from Ross Osborn at Cantor Fitzgerald, which represents a 124.7% increase from the current price of $3.56.
What is the lowest forecasted price for XGN Exagen Inc.?
The lowest price target for XGN is $5.00 from Mark Massaro at BTIG, which represents a 40.4% increase from the current price of $3.56.
What is the overall XGN consensus from analysts for Exagen Inc.?
The overall analyst consensus for XGN is bullish. Out of 5 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are XGN stock price projections?
Stock price projections, including those for Exagen Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
